Worldwide rights position Erasca to advance ERAS-0015 through a unified global development strategyERAS-0015’s promising early clinical data ...
PAS-004 is being tested in a phase 1 trial for MAPK pathway-driven advanced solid tumors, with dosing initiated at 30 mg. The trial is multicenter, open-label, and dose-escalation, assessing safety, ...
ERAS-0015, a pan-RAS molecular glue, will be evaluated in combination with PRMT5 inhibitor vopimetostat. Tango will sponsor the clinical trial and Erasca will supply ERAS-0015 at ...
BOSTON--(BUSINESS WIRE)--Verastem Oncology (Nasdaq: VSTM), a biopharmaceutical company committed to advancing new medicines for patients with RAS/MAPK pathway-driven cancers, today announced that the ...
Organisms sense and respond to changes in the environment through signal transduction pathways. Pathways like highly conserved Mitogen-Activated Protein Kinase (MAPK) pathways are composed of sensor ...
Pasithea Therapeutics Corp. has announced the successful enrollment and initial dosing of three subjects in Cohort 6 of its Phase 1 clinical trial for PAS-004, a candidate for treating ...
Many cancers harbor pro-proliferative mutations of the mitogen-activated protein kinase (MAPK) pathway. In BRAF-driven melanoma cells treated with BRAF inhibitors, subpopulations of cells escape ...
Yeast filamentous growth is a highly regulated cellular differentiation response, enabling cells to assume an elongated morphology when confronted with environmental stress or nutrient limitation.
Psoriasis is characterized by hyperproliferation of keratinocytes and increased expression of integrins, but the pathological signaling pathway remains unknown. In August 15 Journal of Clinical ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results